- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Asthma
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1781KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 355KB)
Dupilumab – November 2020
Dupilumab (asthma): Injection 200 mg in 1.14 mL single use pre-filled syringe, Injection 300 mg in 2 mL single use pre-filled syringe; Dupixent®
Last updated
5 March 2021